We are live on ! Find out more
AKBA icon

Akebia Therapeutics
AKBA

50 hedge funds and large institutions have $200M invested in Akebia Therapeutics in 2014 Q2 according to their latest regulatory filings, with 50 funds opening new positions, increasing their positions, reducing their positions, and 3 closing their positions.

New
Increased
Maintained
Reduced
Closed

9,750% more capital invested

Capital invested by funds: $2.03M → $200M (+$198M)

1,567% more funds holding

Funds holding: 3 → 50 (+47)

1,567% more first-time investments, than exits

New positions opened: 50 | Existing positions closed: 3

Holders
50
Holders Change
+47
Holders Change %
+1,566.67%
% of All Funds
1.44%
Holding in Top 10
1
Holding in Top 10 Change
+1
Holding in Top 10 Change %
% of All Funds
0.03%
New
50
Increased
–
Reduced
–
Closed
3
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
NHAS
Novo Holdings A/S
Denmark
+$36.5M
2
Fidelity Investments
Fidelity Investments
Massachusetts
+$24.5M
3
HM
HealthCor Management
New York
+$21.7M
4
RCM
RA Capital Management
Massachusetts
+$14.4M
5
Franklin Resources
Franklin Resources
California
+$12.3M

Top Sellers

Rank Fund Capital Flow
1
GGHC
Gilder Gagnon Howe & Co
New York
-$1.22M
2
LCM
Laurion Capital Management
New York
-$449K
3
Citadel Advisors
Citadel Advisors
Florida
-$361K
Name Holding Trade Value Shares
Change 		Change in
Stake
NHAS
1
Novo Holdings A/S
Denmark
$42.1M +$36.5M +1,516,387 New
Fidelity Investments
2
Fidelity Investments
Massachusetts
$28.3M +$24.5M +1,019,100 New
HM
3
HealthCor Management
New York
$25M +$21.7M +900,000 New
RCM
4
RA Capital Management
Massachusetts
$16.6M +$14.4M +597,363 New
Franklin Resources
5
Franklin Resources
California
$14.2M +$12.3M +510,400 New
Stifel Financial
6
Stifel Financial
Missouri
$12.4M +$10.7M +444,904 New
CAM
7
Cormorant Asset Management
Massachusetts
$11.1M +$9.63M +400,000 New
Morgan Stanley
8
Morgan Stanley
New York
$11M +$9.55M +396,849 New
BFA
9
BlackRock Fund Advisors
California
$5.36M +$4.64M +192,817 New
Jennison Associates
10
Jennison Associates
New York
$4.97M +$4.31M +178,975 New
EAM
11
Eventide Asset Management
Massachusetts
$4.62M +$4M +166,200 New
Vanguard Group
12
Vanguard Group
Pennsylvania
$4.11M +$3.56M +147,874 New
BIT
13
BlackRock Institutional Trust
California
$2.29M +$1.99M +82,509 New
VAM
14
Visium Asset Management
New York
$2.08M +$1.8M +74,768 New
State Street
15
State Street
Massachusetts
$2.03M +$1.76M +72,982 New
SFM
16
Sphera Funds Management
Israel
$2.02M +$1.75M +72,500 New
BA
17
BlackRock Advisors
Delaware
$1.5M +$1.3M +54,072 New
Norges Bank
18
Norges Bank
Norway
$834K +$722K +30,000 New
Geode Capital Management
19
Geode Capital Management
Massachusetts
$831K +$720K +29,911 New
TCIM
20
TIAA CREF Investment Management
New York
$829K +$718K +29,842 New
Bank of New York Mellon
21
Bank of New York Mellon
New York
$795K +$689K +28,616 New
BG
22
BlackRock Group
United Kingdom
$667K +$578K +24,000 New
BIM
23
BlackRock Investment Management
Delaware
$624K +$541K +22,470 New
Royal Bank of Canada
24
Royal Bank of Canada
Ontario, Canada
$582K +$504K +20,950 New
Northern Trust
25
Northern Trust
Illinois
$577K +$500K +20,761 New
1
2 3

AKBA Hedge Fund Activity: Q2 2014 in Review

50 of the 3,479 institutional investors tracked by Wall St. Rank reported a position in Akebia Therapeutics (AKBA) for Q2 2014, worth a combined $200M — up 9,750% from $2.03M a quarter earlier.

Buyers outnumbered sellers: 50 funds opened new AKBA positions and 3 closed out — a net gain of 47 holders — while 0 added to existing stakes and 0 trimmed.

The largest buyer was Novo Holdings A/S, opening a new position worth an estimated $36.5M. The largest seller was Gilder Gagnon Howe & Co, exiting entirely with an estimated $1.22M sold.

  • 50 institutional investors held Akebia Therapeutics (AKBA) as of Q2 2014, up from 3 in Q1 2014.
  • Funds reported $200M of Akebia Therapeutics stock for Q2 2014, up 9,750% quarter-over-quarter.
  • 50 funds opened new Akebia Therapeutics positions in Q2 2014 and 3 closed out, a net change of +47 holders.
  • The largest Akebia Therapeutics buyer in Q2 2014 was Novo Holdings A/S, an estimated $36.5M added.
  • The largest Akebia Therapeutics seller in Q2 2014 was Gilder Gagnon Howe & Co, an estimated $1.22M sold.

Based on aggregated 13F filings for Q2 2014.